

Research Article

Correlation Between the Exou/Exos Genotype, Biofilm Formation, and Antibiotic Resistance in Pseudomonas Aeruginosa Isolated from Burn Wound Infections

Maryam Ali Raouf^f, Husam Sabah Auhim²

^{1,2}Department of Biology, College of Science, University of Baghdad, Iraq

DOI: <https://doi.org/10.24321/0019.5138.202625>

I N F O

Corresponding Author:

Husam Sabah Auhim, Department of Biology, College of Science, University of Baghdad, Iraq

E-mail Id:

husam.auhim@sc.uobaghdad.edu.iq

Orcid Id:

<https://orcid.org/0000-0003-1086-741X>

How to cite this article:

Raouf M A, Auhim H S. Correlation Between the Exou/Exos Genotype, Biofilm Formation, and Antibiotic Resistance in Pseudomonas Aeruginosa Isolated from Burn Wound Infections. J Commun Dis. 2026;58(2):17-27.

Date of Submission: 2024-06-09

Date of Acceptance: 2026-06-15

A B S T R A C T

Introduction: Pseudomonas aeruginosa is widely recognised as the primary etiological agent for serious infections in burn patients worldwide.

Objective: To examine the frequency of the exoU/exoS genotype in clinical isolates of P. aeruginosa obtained from burn wound infections in Iraq and its correlation with antibiotic resistance.

Methodology: 80 P. aeruginosa isolates were obtained from patients diagnosed with burn wound infections in Iraqi hospitals. The isolates were initially identified by biochemical methods and subsequently confirmed by molecular techniques. Conventional polymerase chain reaction (PCR) was used to detect the exoU/exoS genotype. Antibiotic susceptibility was determined by the disc diffusion method, and biofilm production was assessed by the microtiter plates method.

Results: This study found four distinct genotypes in burn wound infections, with substantial differences ($P < 0.001$). Most P. aeruginosa isolates form biofilm (96.25%; 77/80) at different intensities, with significant differences ($p < 0.05$) and a statistically significant correlation with an (exoS+ \ exoU-) genotype. The (exoS+ \ exoU+) genotype was more antibiotic-sensitive. While the (exoS- \ exoU+) genotype was more antibiotic-resistant than other genotypes. The genotype exoU+ \ exoS- correlated significantly with fluoroquinolone antibiotic susceptibility, resulting in substantial resistance rates against ciprofloxacin and levofloxacin. While the genotype exoU+ \ exoS+ showed a statistically significant correlation with susceptibility to cephalosporin antibiotic groups (ceftazidime and cefepime), the sensitivity rate was higher than other genotypes.

Conclusion: These results suggested that genotype influences antibiotic resistance, posing a concern, as horizontal gene transfer of the exoU gene can increase antibiotic resistance in P. aeruginosa.

Keywords: Pseudomonas Aeruginosa, exoU/exoS Genotype, Type III Secretion System, Burn Wound Infections, Biofilm Formation

Introduction

Pseudomonas aeruginosa is a Gram-negative bacterium highly prevalent in various environments and recognized as a primary etiological agent of healthcare-associated diseases.^{1,2} *P. aeruginosa* is a significant contributor to mortality and morbidity in individuals with compromised immune systems, including those who have suffered burns.³ The presence of this bacterium in hospitals can lead to a range of serious diseases in hospitalized individuals, including septicemia, otitis, endocarditis, pneumonia, keratitis, and skin and soft tissue infections.⁴ Furthermore, due to innate or acquired resistance to many broad-spectrum antibiotics, *P. aeruginosa* has become a prevalent pathogen in hospital environments.^{5,6} Patients with compromised immune systems, such as those who have recently had burn treatments, are particularly vulnerable to infection with *P. aeruginosa*.⁷ The mortality rate among burn patients who are infected is greater compared to burn patients who are not infected, mainly when the infection is caused by multidrug-resistant bacteria (MDR). The investigation and characterization of bacterial isolates associated with burn wound infections have received significant attention due to the frequent occurrence of MDR *P. aeruginosa* infections in burn units.^{8,9}

Various protein secretion systems can release proteins into the surrounding environment or into the host cell. The type III secretion system, also known as TTSS or T3SS, is the third type of secretion system found in bacterial cells. It appears to be a needle in the structure of pathogenic bacteria¹⁰, and it functions as a sensory transmitter to detect eukaryotic organisms. It releases proteins that facilitate the spread of bacterial infections. Exoenzymes or effector proteins are secreted directly from the bacterial cell into the eukaryotic host cell by this system, where they exert various effects. This helps the pathogen survive, resist, and evade the immune response. *P. aeruginosa* secretes four types of exoenzymes via T3SS: S, Y, U, and T exoenzymes.¹¹ Bacteria that possess this system produce exo Y and exo T in 100 %, while others (exo S and exo U) are present in different percentages. However, new isolates appeared to have both genes (exoS and exoU) in addition to the other two genes, exoY and exoT. These isolates are classified as highly virulent, containing all four toxins.¹²

The relevant literature reports a correlation between biofilm formation and the exoU-/exoS+ genotype.¹³ Derakhshan et al. reported that 100% of biofilm-producing isolates contain the exoS gene.¹⁴ With regard to antibiotics, the association between antimicrobial resistance (or MDR phenotype) and type III secretion system genes was most investigated for the exoU gene.¹⁵ As previously indicated, this gene is associated with increased resistance to certain antibiotics, and the exoU gene is more commonly found in MDR *P.*

aeruginosa strains.¹⁶ Acquiring knowledge of these genetic types and their associations with antibiotic resistance and biofilm formation will enable us to understand the importance of these genes in disease development.

Material and methods

Specimens' collection, bacterial isolation, and identification. A total of 120 burn swabs have been collected from two hospitals in Baghdad, namely the Teaching Baghdad Hospital and AL-Yarmok Hospital, over the period of January to April 2023. The swabs were cultured on MacConkey agar and then incubated at 37°C for 24 hours. In addition to microscopic examination, a selective cetrimide medium and biochemical tests, including oxidase, catalase, and incubation at different temperatures (4 and 42 °C), were used for the primary identification. The identity was ultimately confirmed by molecular techniques that targeted a fragment of the 16S rRNA gene with specific primers. The identified bacterial isolates were cultivated and stored at 4°C for subsequent examination.

Oligonucleotide primers

The in-silico design of oligonucleotide primers was carried out using Serial Cloner 2-6-1 and Amplifx software. First, the sequences of the target genes were downloaded from the National Center for Biotechnology Information (NCBI) website. The accession number for the 16SrRNA gene was (PP448158.1), and for exoS and exoU, were (X99471.1) and (KX641459.1), respectively. The primers were manufactured by Macrogen Company and provided in a lyophilized form. A stock solution of primer (100 pmol/μl) was prepared by dissolving the lyophilized primer in an appropriate amount of nuclease-free water, according to the manufacturer's instructions. Then, the working solution (10 pmol/μl) was prepared by diluting the stock solution ten times and kept at -20° C in the freezer; a list of the primers is shown in Table 1. Thermo Fisher Scientific's Tm Calculator was used to calculate the annealing temperatures for primers.¹⁷

Whole bacterial genomic extraction

This study employed a novel technique to efficiently extract whole bacterial genomes, with potential for use in gene exploration. This strategy combines and adapts the boiling method described by Omar et al.¹⁸ and the colony PCR technique used by Husam¹⁹. In the present experiment, a single bacterial colony was transferred into a 5 ml nutritional broth and incubated for 24 hours at 37°C. Next, cells were collected by centrifugation at 13000 rpm for 15 minutes. The recovered cells were washed twice with 1 ml of distilled water and resuspended in another 1 ml. The cells were then standardized to achieve an optical density (O.D.) value of 1 at a wavelength of 600 nm. Subsequently, 0.3 ml of the standardized bacterial culture was transferred into an Eppendorf tube. The cells were subsequently collected by

centrifuging for 15 minutes at 13000 rpm. Following this, the cells were resuspended in 0.75 ml of Tris-EDTA buffer (TE) and subsequently heated to 100°C for 10 minutes. The denatured proteins and cellular debris were removed from the genomic DNA using centrifugation for 20 minutes at 13000 rpm. The genomic DNA-containing supernatant was used as a direct PCR template without additional purification, with a supernatant-to-PCR reaction mixture ratio of 1:9.

Amplification of genes by polymerase chain reaction (PCR) technique

The conventional PCR technique was employed to amplify segments of three target genes: the 16SrRNA gene for molecular bacterial identification and the *exoS* and *exoU* genes to investigate the prevalence of the *exoS/exoU* genotype among *P. aeruginosa* isolates. The reaction mixture and PCR settings for amplifications using Go Taq G2 Green Master Mix are provided in Table 2. All PCR reactions were performed using sterile PCR tubes and an Applied Biosystems thermocycler.

Table 1. Primers sequences, annealing temperatures, and amplicon sizes

Primer name	5- Sequence -3	Annealing temperatures (°C)	Amplicon size bp
For 16s rRNA gene (bacterial identification)			
16S Pseud-F	AGGCTAACACATGCAAGTCGA	55	1400
16S Pseud-R	GGTTAGACTAGCTACTTCTGGAGC		
For <i>exo U</i> gene detection			
ExoU-F	CCGTTGTGGTGCCGTTGAAG	57	800
ExoU-R	TCATGTGAACTCCTTATCCGCC		
For <i>exo S</i> gene detection			
ExoS-F	GCGGACCTGAATCGCGCTCT	55	500
ExoS-R	CGTACATCTGTTCTGGACC		

Table 2. Composition of PCR Mixture and PCR conditions

Materials			Volume in µl		
Go Taq G2 Green Master Mix (2X)			50		
Forward Primer (10 µM/ µl)			1.5		
Reverse Primer (10 µM/ µl)			1.5		
Ultra-pure water			47		
Total reaction mixture			100		
Aliquot 9.5 µl into 10 PCR tubes and add 1 µl of DNA-containing supernatant					
PCR conditions					
Initial denaturation	30 reaction cycles			Final Extension	Hold
	Denaturation	Annealing	Extension		
5 min (95°C)	30 s (95°C)	30 s (X°C) *	50 s (72°C)	5 min (72°C)	5 min (4°C)
* X= Tm used according to the primer pairs listed in Table 1					

Agarose gel electrophoresis

The PCR results were analysed using agarose gel electrophoresis, using 2% (w/v) agarose gel. The agarose gels were prepared by dissolving 2 g of agarose powder (Promega, USA) in 100 ml of 1X TAE (40 mM Tris-acetate, 1 mM EDTA, pH 8.8) using a microwave. After cooling to approximately 50-40°C, the gel was then enhanced with 4 µl of ethidium bromide (10 mg/mL, Promega, USA).

Subsequently, the gel was poured into a gel tray and left to solidify at room temperature (20-25°C). A volume of 5 µl of each sample was subjected to analysis with a volume of 3 µl of a DNA ladder (1 kb DNA, Promega, USA). The electrophoresis procedure was conducted at a voltage of 75 volts for 60 minutes. The DNA bands were detected using ultraviolet (UV) light in a gel imaging device (Fisher Scientific, UK).

Assessment of biofilm formation by bacterial isolates

The biofilm development experiment used a microtiter plate approach, as outlined by Djordjevic et al.²⁰ In summary, isolates were cultured in brain heart infusion (BHI) broth at 37°C for 24 hours. Subsequently, it underwent calibration using a McFarland standard of 0.5. Three wells of the sterile polystyrene microplate with a U-shaped bottom and 96 wells filled with 180 µl of BHI and 20 µl of calibrated bacterial culture. The plate was sealed and incubated for 24 hours at 37°C. Negative controls were conducted using BHI broth wells. Following incubation, the sample was subjected to three gentle rinses using distilled water. Subsequently, it was dried at 65°C for one hour. Next, methanol was applied to fix the biofilm for 30 minutes, followed by washing with distilled water. For staining the biofilm, the plates were incubated for 10 minutes at room temperature with 200 µL of a 1% crystal violet solution. Subsequently, the plates were washed with distilled water and dehydrated for 30 minutes at 37°C. 200 µl of glacial acetic acid was added to dissolve the cells adhering to the surface, and the optical density (OD) at 580 nm was measured for each well using a Microplate ELISA reader (Diagnostic Automation, Inc., USA). The cut-off optical density (ODC) is defined as three standard deviations (SD) above the average OD of the negative control. The ODC is calculated as follows: $ODC = \text{average OD of negative control} + (3 \times \text{standard deviation of negative control})$. The isolates were classified into four categories according to their ODC value: $OD \leq ODC$ indicates a non-producer of biofilm. $ODC < OD \leq 2 * ODC$ signifies a weak biofilm producer. $2 * ODC < OD \leq 4 * ODC$ represents a moderate biofilm producer, while $4 * ODC < OD$ indicates a strong biofilm producer.

Antibiotic susceptibility patterns test

The antibiotic susceptibility patterns were assessed using the disk diffusion method on Mueller-Hinton agar plates, following the recommendations provided by CLSI 2023 and the protocol reported by Velican et al.²¹ The antimicrobial discs used in the study were Amikacin (AK, 30 µg), Gentamycin (GN, 10 µg), Imipenem (IMP, 10 µg), Meropenem (MEM, 10 µg), Ceftazidime (CAZ, 30 µg), Cefepime (FEP, 30 µg), Ciprofloxacin (CIP, 5 µg), Levofloxacin (LEV, 5 µg), Piperacillin-tazobactam (TPZ, 100\10 µg) and Ticarcillin-clavulanate (TCC, 75\10 µg). *P. aeruginosa* isolates were categorized as resistant, sensitive, or intermediate by comparing the inhibition zone diameter to the CLSI, 2023 recommendations, after incubating at 37° C for 24 hours.

Statistical analysis

All features were presented as frequencies and percentages, and the Pearson chi-square test was used

to assess significant differences in percentages. $P \leq 0.05$ was considered significant. The data were analyzed using SPSS v. 22.0 and Excel 2013 statistical software.

Results and Discussion

Primary bacterial isolation and identification

A total of 80 *P. aeruginosa* isolates (66.6%) were isolated from 120 patients diagnosed with burn wound infections in Iraqi hospitals, compared to 40/120 (33.32%) for other microbial growth, with significant differences ($p < 0.05$). The primary identification of *P. aeruginosa* isolates was based on culturing characteristics on selective and differential medium, microscopic examination, and a few biochemical tests, as illustrated in Table 3.

Table 3. Results of cultural characteristics and biochemical tests of *P. aeruginosa* isolates

Tests	Result
Growth on MacConkey Agar	Lactose non-fermenter, pale colony
Growth on Cetrimide agar	A present fluorescent green colour with growth
Gram stain	Gram negative, Bacilli
Oxidase test	Positive
Catalase test	Positive
Grow at 42°C	Positive
Grow at 4°C	Negative

Primary identification is considered an essential step in isolating bacteria from infection sites. This identification helps avoid other uninteresting bacteria that may be involved in infections, thereby saving time and materials, especially since many bacterial species can cause infections in burn wounds.^{22,23} However, the identification of the 80 bacterial isolates was confirmed using a molecular technique by targeting a segment of the 16S rRNA gene (1400 pb) that shares 100% identity with *P. aeruginosa* using specifically designed primers. Four sets of results are illustrated in Figure 1, each representing a different group of isolates (1 to 20, 21 to 40, 41 to 60, and 61 to 80). The consistency of the banding patterns across all samples, as shown in Figure 1, indicates the existence and successful amplification of the target 16S rRNA gene, confirming the identity of the isolates as *P. aeruginosa*.²⁴ This demonstrates the reliability and precision of this molecular technique in bacterial identification. This technique achieved high accuracy^{25,26} confirming the identity of bacterial isolates.




Figure 1. Agarose gel electrophoresis (2%) of PCR amplicon showing a segment of 16S rRNA gene (1400 bp) amplification for *P. aeruginosa* identification.

Numbers 1 to 80 correspond to *P. aeruginosa* isolates. M corresponds to the DNA marker (100 bp).

Molecular detection of *exoU/exoS* genotype amongst *P. aeruginosa*

Two genes were targeted to determine the *exoU/exoS* genotype: *exoU* and *exoS*. The results showed a variable distribution of the *exoU* and *exoS* genes among the bacterial isolates under study with significant differences ($P < 0.001$), as shown in Figure 2. This distribution categorized the *P. aeruginosa* isolates into four genotypes. The first genotype (*exoU*-/*exoS*+), which was the highest one, was found in 75% (60/80) of the bacterial isolates. In contrast, the second genotype (*exoU*-/*exoS*-) was relatively rare, found in only 5% (4/80) of the bacterial isolates, indicating a lack of both key virulence factors. The third and most important one was the (*exoU*+/*exoS*+) genotype, indicating the presence of both virulence factors, which was observed in 13.75% (11/80) of the isolates. Lastly, the fourth genotype (*exoU*+/*exoS*-) was detected in 6.25% (5/80) of isolates. The results are in line with another local study that found that *exoS* and *exoU* genes were present in 90.47% and 60.31% of *P. aeruginosa* isolates from different clinical sources, respectively.²⁷

Biofilm formation and correlation with *exoU/exoS* genotype

The results showed that 96.25% (77/80) of the isolates formed biofilm. In comparison, 3.75% of isolates (3/80) were non-biofilm formers with significant differences ($p < 0.05$) under laboratory conditions. The positive biofilm-forming isolates (77) revealed different levels of biofilm formation. Strong biofilm producers (38.96%), followed by moderate- biofilm producers (35.06%) and weak biofilm producers (25.97%), as shown in Table 4. In general, most isolates are biofilm producers, with the highest prevalence

among strong-intensity biofilm producers, followed by moderate and weak-intensity biofilm producers. Several researchers have reported similar results. In the previous investigation, all *P. aeruginosa* isolates obtained from infected wounds and burns were found to be capable of producing biofilms (100%). Among these isolates, 50% were classified as strong biofilm producers, 37% as moderate biofilm producers, and 13% as weak biofilm producers. Ghasemian et al. reported that all *P. aeruginosa* isolates isolated from burn wounds were biofilm producers, of which 42.5%, 35%, and 22.5% were strong, moderate, and weak biofilm producers, respectively 28. Similarly, Tiba and Huda reported that 100% of *P. aeruginosa* isolates were biofilm producers. The prevalence of isolates forming biofilm was 52%, 32%, and 16% for strong, moderate, and weak biofilm, respectively.²⁹




Figure 2. Agarose gel electrophoresis (2%) of PCR amplicon showing amplification of a segment of *exoU* gene (800 bp) and *exoS* gene (500 bp) for *P. aeruginosa*. Numbers 1 to 80 correspond to *P. aeruginosa* isolates. M corresponds to the DNA marker (100 bp). Each line in the gel represented a combination of separated PCR products for *ExoU* and *ExoS*

Table 4. Frequency and percentage of biofilm types in P. aeruginosa isolates

Biofilm formation	Number of isolates	Percentage	P value
Non-producers	3	3.75%	P<0.05**
Producers	77	96.25%	
Total	80	100%	
Type of biofilm in biofilm producer isolates			
Strong producers	30	38.96%	p<0.05
Moderate producers	27	35.06%	
Weak producers	20	25.97%	
Total	77	100%	

The ability to form a biofilm is controlled by a variety of components and biofilm-related genes, which play a role in the initial attachment of *P. aeruginosa* to surfaces.³⁰ These components include flagella, type IV pili, Cup fimbriae, extracellular DNA (eDNA), Psl polysaccharides, and alginate.³¹ Biofilm formation would also be due to the release of compounds such as iron siderophores and biosurfactants into the surrounding environment.³² However, variation in the quality and quantity of autoinducers produced by each isolate, as well as genetic factors and other components that affect biofilm formation, could explain isolates' ability to generate different biofilm intensities.^{33,34}

Statistical analysis of the distribution of the genotype amongst the biofilm producers revealed a significant correlation (P<0.05) between biofilm formation and the *exoU*-/*exoS*+ genotype; 75.32% (58/77) of biofilm producer isolates were *exoU*-/*exoS*+, followed by *exoU*+/*exoS*+, which accounted for 12.98% (10/77) of biofilm producer isolates, with no significant difference. In contrast, the genotypes that lack the *exoS* gene represented a lower percentage among biofilm-producing isolates: 5.1% (4/77) and 6.49% (5/77) for *exoU*-/*exoS*- and *exoU*+/*exoS*- genotypes, respectively, as shown in Table 4. Results revealed no correlation between biofilm types and other genotypes.

Edward and Cottage showed 75% of isolates that have the *exoS* gene produce biofilm³⁵, and these results were lower than our study, which showed (88.31%; *exoU*-/*exoS*+ (75%) + *exoU*+/*exoS*+(12.98%)) of isolates that produce biofilm have *exoS*. Another study revealed similar results. The *exoU*-/*exoS*+ genotype was the most common in biofilm-producer isolates (79.8%)¹³. Derakhshan et al. reported that 100% of biofilm-producing isolates carried the *exoS* gene¹⁴.

The high prevalence of the *exoS* gene in biofilm producers could be explained by the importance of the *ExoS* toxin in the spread and pathogenicity of bacterial isolates, as it is known to be an invasive factor. Our results contribute to understanding the complex interplay between genotypic variation and biofilm-forming capabilities in *P. aeruginosa* and suggest that biofilm formation is a complex trait influenced by multiple factors, including, but not limited to, genotype, as discussed in several studies.^{36,37}

Antibiotic susceptibility patterns and correlation with *exoU*/*exoS* genotype

The sensitivity of *P. aeruginosa* to various antibiotics has been the subject of numerous studies owing to the bacterium's capacity to acquire resistance³⁸. Ten different antibiotic agents belong to five groups; two antibiotics from each group were used to evaluate antibiotic susceptibility patterns and investigate the potential correlation between antibiotics and different (*exoU*/*exoS*) genotypes in *P. aeruginosa* isolates. Based on the results illustrated in Figure 3, the isolates were found to have a broad spectrum of resistance from 86.3% against each of Ceftazidime and Cefepime to 18.8% against each of Ciprofloxacin and Levofloxacin; a wide range of sensitivity from 78.8% against Ciprofloxacin to 13.8% against each of Ceftazidime and Cefepime; and a wide range of intermediate susceptibility from 28.8% against Ticarcillin-clavulanate to 0% against each of Ceftazidime and Cefepime.

Biofilm Genotypes

As shown in the figure above, most of the bacterial isolates were resistant to the Cephalosporin group of antibiotics (Ceftazidime and Cefepime, with a resistance rate of 86.3%). These results are in line with a previous local study in Iraq that reported that isolated *P. aeruginosa* from burns were resistant to Ceftazidime and Cefepime at rates of 84.50% and 85.92%, respectively.³⁹ However, an international investigation showed the opposite results regarding Ceftazidime and Cefepime; it has been reported that *P. aeruginosa* isolated from burns was sensitive to Ceftazidime and Cefepime at rates of 59.3% and 77.8%, respectively.⁴⁰ The resistance of *P. aeruginosa* to cephalosporin antibiotics can result from the induction of chromosomal β -lactamases upon exposure to these antibiotics.⁴¹

It can be seen that all isolates showed different sensitivity patterns to the antibiotics under investigation. The highest sensitivity rates were 78.8%, 75%, and 68.8% for Ciprofloxacin, Piperacillin-tazobactam, and Levofloxacin, respectively. These findings are similar to those reported by Abdi et al., who found that Piperacillin-tazobactam and Ciprofloxacin had high sensitivity rates of 74.1% and 66.67%, respectively⁴⁰. These antibiotics can be recommended as effective antibacterials for the treatment of burn wound infections caused by *P. aeruginosa*.

Table 5. Comparison of biofilm types with (ExoU/ExoS) genotype in *P. aeruginosa* isolates

Biofilm U(+)/S(+) Positive Negative			Genotypes							
			U(-)/S(-)		U(+)/S(-)		U(-)/S(+)		Positive	Negative
			Positive	Negative	Positive	Negative	Positive	Negative		
Non	N	1	2	0	3	0	3	2	1	
	%	9.1%	2.9%	0.0%	3.9%	0.0%	4%	3.3%	5%	
Weak	N	2	18	0	20	3	17	15	5	
	%	18.2%	26.1%	0.0%	26.3%	60%	22.7%	25%	25%	
Moderate	N	4	23	3	24	0	27	20	7	
	%	36.4%	33.3%	75%	31.6%	0.0%	36%	33.3%	35%	
Strong	N	4	26	1	29	2	28	23	7	
	%	36.4%	37.7%	25%	38.2%	40%	37.3%	38.3%	35%	
Total %	N	11	69	4	76	5	75	60	20	
	100%	100%	100%	100%	100%	100%	100%	100%		
P value		P>0.05		P>0.05		P>0.05		P>0.05		
Total Biofilm Producers		10		4		5		58		
%		12.98 %		5.1%		6.49%		75.32%		
P value		P>0.05		P>0.05		P>0.05		P>0.05**		

Other antibiotics under investigation, including Imipenem, Amikacin, Gentamicin, Meropenem, and Ticarcillin-clavulanate, showed a wide range of resistance, sensitivity, and intermediate susceptibility. These differences in antibiotic susceptibility patterns between all the antibiotics under study, as well as in other studies, are a result of the fact that several factors affect antibiotic susceptibility, such as the presence of resistant genes, efflux pumps, biofilm, its exogenous DNA, and other 42,43. Furthermore, there are three fundamental mechanisms of antimicrobial resistance (1) enzymatic degradation of antibacterial drugs, (2) alteration of bacterial proteins that are antimicrobial targets, and (3) changes in membrane permeability to antibiotics 31. These factors and mechanisms vary among bacterial isolates, resulting in different responses to antibiotics.

The susceptibility of *P. aeruginosa* to various antibiotics and its correlation with other virulence factors has been a topic of interest in many studies, given the bacterium's ability to develop resistance to antibiotics 44,45,38. However, only two genotypes ($exoU^+exoS^-$ and $exoU^+exoS^+$) have been found to correlate with the antibiotics under investigation, while other genotypes ($exoU^-exoS^-$ and $exoU^-exoS^+$) showed no correlation.

The $exoU^+exoS^-$ genotypes showed a statistically significant correlation with susceptibility against fluoroquinolone antibiotic groups (Ciprofloxacin and Levofloxacin). This genotype showed a high resistance rate against these antibiotics, which was 60% for both compared with other genotypes that showed a lower resistance rate against the same antibiotics. For Ciprofloxacin, the resistant rates were 0%, 25%, and 18.3% for $exoU^+exoS^+$, $exoU^-exoS^-$, and $exoU^-exoS^+$ genotypes, respectively, and for Levofloxacin, the resistant rates were 0%, 0%, and 20% for $exoU^+exoS^+$, $exoU^-exoS^-$, and $exoU^-exoS^+$ genotypes, respectively, as shown in Figure 4. Similar findings were reported by Sawa et al.; the presence of the $exoU^+$ genotype correlates with a fluoroquinolone resistance phenotype 46. According to Subedi et al., all isolates that harbored the $exoU$ gene exhibited higher resistance to fluoroquinolones 47. Furthermore, these isolates showed high resistance to all antibiotics under study. Figure 4 clearly shows that the $exoU^+exoS^-$ genotypes exhibited higher resistance to most antibiotics under investigation than other genotypes. This is a concerning sign; the cytotoxic genotype is more resistant to antibiotics, especially with the possibility of transferring the $exoU$ gene between bacterial isolates, which could increase antibiotic resistance rates. These findings align with other investigations that revealed the

presence of the *exoU* gene associated with high antibiotic resistance. The *exoU* gene is often found amongst MDR *P. aeruginosa* strains 16. Higher antimicrobial resistance is generally observed in *P. aeruginosa* isolates possessing the *exoU* gene.⁴⁸

Interestingly, a statistically significant correlation between the genotype *exoU*+/*exoS*+ and the Cephalosporin antibiotic groups (Ceftazidime and Cefepime) has been observed, as shown in Figure 4; this is the first report of such a correlation. The sensitivity rate was 36.4% for the above antibiotics, whereas other genotypes (*exoU*-/*exoS*- and *exoU*-/*exoS*+) showed 0% sensitivity to the same antibiotics. Interestingly, the genotype *exoU*-/*exoS*+ showed an 11.7% sensitivity rate. Based on the above results, the presence of the *exoS* gene may affect *P. aeruginosa*'s susceptibility to the cephalosporin antibiotic groups under investigation.




Figure 4. Antibiotic susceptibility pattern of ten different antibiotics tested against different genotypes of *P. aeruginosa* isolates. Amikacin (AK), Gentamycin (GN), Imipenem (IMP), Meropenem (MEM), Ceftazidime (CAZ), Cefepime (FEP), Ciprofloxacin (CIP), Levofloxacin (LEV), Piperacillin-tazobactam (TPZ) and Ticarcillin-clavulanate (TCC)

The association of the *exoU*+ genotype with fluoroquinolones has been found to be linked with quinolone resistance-determining regions (QRDRs), topoisomerase II (*gyrA* and *gyrB*), and topoisomerase IV (*parC* and *parE*), mutations in these genes have been shown to increase fluoroquinolone resistance in *P. aeruginosa*.⁴⁹ Furthermore, it was noted that fluoroquinolone resistance in *ExoU* strains was associated with a specific combination of mutations in *gyrA* and *parC*. Sequence analysis revealed that six out of eight *exoU* strains exhibited at least one mutation in either *gyrA* (T831) or *parC* (S87L)⁴⁷. Regarding cephalosporin correlation, as reported here for the first time, the association with cephalosporin groups is unclear. Therefore, further investigation is needed to understand the correlation better. It is worth noting that antibiotic susceptibility can be influenced by many

factors, including the presence of resistance genes, the expression of efflux pumps, and the ability to form biofilms.⁵⁰ Therefore, the correlation between *exoU*/*exoS* genotypes and antibiotic susceptibility is complex, given the number of genes and factors involved.

Conclusion

Different genotypes of *P. aeruginosa* are present in burn wound infections in Iraq, as indicated by the presence of Type III secretion system toxins, with the *exoS*+/*exoU*- genotype (invasion genotype) being highly prevalent. The most virulent genotype (*exoS*+/*exoU*+, which is invasive and cytotoxic) is more sensitive to antibiotics than other genotypes. Therefore, the elimination of this genotype could be controlled. While the *exoS*-/*exoU*+ genotype (cytotoxic genotype) is more resistant to antibiotics than other genotypes, this is a worrisome sign, especially when *exoU* can transfer via horizontal gene transfer, which, in turn, raises antibiotic resistance in *P. aeruginosa*.

Ethical Approval

All participants agreed to provide the investigator with the specimens. The Ethics Committee of the College of Science at the University of Baghdad authorized this work (Ref. CSEC/0123/0008). All participants provided informed consent in accordance with the Declaration of Helsinki.

Acknowledgement

We thank all people who supported this work.

Source of Funding: None

Conflict of Interest: None

References

1. Wang X, Gao K, Chen C, Zhang C, Zhou C, Song Y, Guo W. Prevalence of the virulence genes and their correlation with carbapenem resistance amongst the *Pseudomonas aeruginosa* strains isolated from a tertiary hospital in China. *Antonie Van Leeuwenhoek*. 2023 Dec;116(12):1395-406. [Google Scholar] [PubMed]
2. Bassi AG, Al-Rubaii BA. Detection of pyocin S and the effects of lactobacillus acidophilus cell-free supernatants on multi-drug resistant *Pseudomonas aeruginosa* isolated from patients of Baghdad Hospitals. *Journal of Communicable Diseases*. 2024;56(1):135-44. [Google Scholar]
3. Fakhry AK, Aljanabi AO. The effect of pseudomonas infection with burns patients. *Journal of Current Medical Research and Opinion*. 2024 Feb 20;7(02):2135-57. [Google Scholar]
4. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, Liang H, Song X, Wu M. *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics.

- Signal transduction and targeted therapy. 2022 Jun 25;7(1):199. [Google Scholar] [PubMed]
5. Agyeman WY, Bisht A, Gopinath A, Cheema AH, Chaludiya K, Khalid M, Nwosu M, Konka S, Khan S. A systematic review of antibiotic resistance trends and treatment options for hospital-acquired multidrug-resistant infections. *Cureus*. 2022 Oct 5;14(10):e29956. [Google Scholar] [PubMed]
 6. Khorshid NF, Odaa NH. Optimum Conditions for Pyomelanin Production and Characterization from Local Isolates of *Pseudomonas aeruginosa*. *Medical Journal of Babylon*. 2025 Jan 1;22(1):108-16. [Google Scholar]
 7. Tuon FF, Cieslinski J, Rodrigues SD, Serra FB, Paula MD. Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil-the EM200 study. *Brazilian Journal of Infectious Diseases*. 2020 Jun 26;24(2):96-103. [Google Scholar] [PubMed]
 8. Ellithy M, Mitwally H, Saad M, Mathias R, Shaukat A, Elzeer H, Hassan Koya S, Mahmood Z, Gazwi K. Mortality incidence among critically ill burn patients infected with multidrug-resistant organisms: A retrospective cohort study. *Scars, Burns & Healing*. 2021 May;7:20595131211015133. [Google Scholar] [PubMed]
 9. Abed MN, Rasheed HM. Effect of some sugars on carbapenemase gene expression in *Pseudomonas aeruginosa*. [Google Scholar]
 10. Naito Y, Moriyama K, Sawa T. Anti-PcrV immunization for *Pseudomonas aeruginosa* pneumonia in cystic fibrosis. *Progress in understanding cystic fibrosis*. 2017 Jul 12:159-73. [Google Scholar]
 11. Jurado-Martín I, Sainz-Mejías M, McClean S. *Pseudomonas aeruginosa*: an audacious pathogen with an adaptable arsenal of virulence factors. *International journal of molecular sciences*. 2021 Mar 18;22(6):3128. [Google Scholar] [PubMed]
 12. Jarjees KK. Molecular detection of type III secretory toxins in *Pseudomonas aeruginosa* isolates. *Cellular and Molecular Biology*. 2020 Jul 31;66(5):9-14. [Google Scholar] [PubMed]
 13. Olaniran OB, Donia A, Adeleke OE, Bokhari H. Prevalence of Type III Secretion System (T3SS) and Biofilm Development in Genetically Heterogeneous Clinical Isolates of *Pseudomonas aeruginosa* from Nigeria. *Current Microbiology*. 2023 Nov;80(11):349. [Google Scholar] [PubMed]
 14. Derakhshan S, Rezaee A. Relationship between type III secretion toxins, biofilm formation, and antibiotic resistance in clinical *Pseudomonas aeruginosa* isolates. *Инфекция и иммунитет*. 2021;11(6):1075-82. [Google Scholar]
 15. AL-Shamaa NF, Abu-Risha RA, AL-Faham MA. Virulence genes profile of *Pseudomonas aeruginosa* local isolates from burns and wounds. *Iraqi journal of biotechnology*. 2016;15(3). [Google Scholar]
 16. Zhu Y, Kang Y, Zhang H, Yu W, Zhang G, Zhang J, Kang W, Duan S, Xu Y, Yang Q. Emergence of ST463 exoU-positive, imipenem-nonsusceptible *Pseudomonas aeruginosa* isolates in China. *Microbiology Spectrum*. 2023 Aug 17;11(4):e00105-23. [Google Scholar] [PubMed]
 17. Allawi HT, SantaLucia J. Thermodynamics and NMR of internal G-T mismatches in DNA. *Biochemistry*. 1997 Aug 26;36(34):10581-94. [Google Scholar] [PubMed]
 18. Ahmed OB, Asghar AH, Elhassan MM. Comparison of three DNA extraction methods for polymerase chain reaction (PCR) analysis of bacterial genomic DNA. *African Journal of Microbiology Research*. 2014 Feb 5;8(6):598-602. [Google Scholar]
 19. Al-Maslookhi H. Structure, function and engineering of biotechnologically important proteins (Doctoral dissertation, Cardiff University). [Google Scholar]
 20. Djordjevic D, Wiedmann M, McLandsborough LA. Microtiter plate assay for assessment of *Listeria monocytogenes* biofilm formation. *Applied and environmental microbiology*. 2002 Jun;68(6):2950-8. [Google Scholar] [PubMed]
 21. Velican AM, Măruțescu L, Kamerzan C, Cristea VC, Banu O, Borcan E, Chifiriuc MC. Rapid detection and antibiotic susceptibility of uropathogenic *Escherichia coli* by flow cytometry. *Microorganisms*. 2020 Aug 13;8(8):1233. [Google Scholar] [PubMed]
 22. Hussien IA, Habib KA, Jassim KA. Bacterial colonization of burn wounds. *Baghdad Science Journal*. 2012;9(4):8. [Google Scholar]
 23. Ghafil JA, Flieh M. Isolation and identification of bacterial burn wound infection in Iraqi patient. *Indian Journal of Forensic Medicine & Toxicology*. 2021 Oct 1;15(4). [Google Scholar]
 24. Sulaiman SD, Abdulhasan GA. Curcumin as efflux pump inhibitor agent for enhancement treatment against multidrug resistant *Pseudomonas aeruginosa* isolates. *Iraqi Journal of Science*. 2020 Jan 26:59-67. [Google Scholar]
 25. Ullah N, Güler E, Güvenir M, Arkan A, Süer K. Isolation, identification, and antibiotic susceptibility patterns of *Pseudomonas aeruginosa* strains from various clinical samples in a university hospital in Northern Cyprus. *Cyprus J Med Sci*. 2019 Dec 1;4(3):225-8. [Google Scholar]
 26. Auhim HS, Odaa NH. Molecular detection and the frequency of a pore-forming toxin in *Enterococcus*

- faecalis isolated from urinary tract infections. *Microbes and Infectious Diseases*. 2025 May 1;6(2):948-56. [Google Scholar]
27. AL-Mayyahi AW, AL-Hashimy AB, AL-Awady KR. Molecular detection of *exoU* and *exoS* among *Pseudomonas aeruginosa* isolates from Baghdad and Wasit, Iraq. *Iraqi journal of biotechnology*. 2018 Nov 12;17(1). [Google Scholar]
28. Ghasemian S, Karami-Zarandi M, Heidari H, Khoshnood S, Kouhsari E, Ghafourian S, Maleki A, Kazemian H. Molecular characterizations of antibiotic resistance, biofilm formation, and virulence determinants of *Pseudomonas aeruginosa* isolated from burn wound infection. *Journal of clinical laboratory analysis*. 2023 Feb;37(4):e24850. [Google Scholar] [PubMed]
29. Al-Mohammed TA, Mahmood HM. Carbapenem resistance related with biofilm formation and pilin genes in clinical *Pseudomonas aeruginosa* isolates. *Iraqi Journal of Pharmaceutical Sciences*. 2024 Mar 26;33(1):72-8. [Google Scholar]
30. Ahmed NA, Almohaidi AM. Investigation of biofilm formation ability and Assessment of *cupB* and *rhIR* Gene Expression in Clinical Isolates of *Pseudomonas aeruginosa*. *Iraqi journal of biotechnology*. 2022;21(2). [Google Scholar]
31. Fernández-Billón M, Llambías-Cabot AE, Jordana-Lluch E, Oliver A, Macià MD. Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa* biofilms. *Biofilm*. 2023;5:100129. [Google Scholar] [PubMed]
32. Chimi LY, Noubom M, Bisso BN, Singor Njateng GS, Dzoyem JP. Biofilm Formation, Pyocyanin Production, and Antibiotic Resistance Profile of *Pseudomonas aeruginosa* Isolates from Wounds. *Int J Microbiol*. 2024;2024:1207536. [Google Scholar] [PubMed]
33. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. Osteomyelitis and the role of biofilms in chronic infection. *FEMS Immunol Med Microbiol*. 2008;52(1):13-22. [Google Scholar] [PubMed]
34. Beenken KE, Mrak LN, Griffin LM, Zielinska AK, Shaw LN, Rice KC, Horswill AR, Bayles KW, Smeltzer MS. Epistatic relationships between *sarA* and *agr* in *Staphylococcus aureus* biofilm formation. *PloS one*. 2010 May 24;5(5):e10790. [Google Scholar] [PubMed]
35. Edwards YJ, Cottage A. Bioinformatics methods to predict protein structure and function: A practical approach. *Molecular biotechnology*. 2003 Feb;23(2):139-66. [Google Scholar] [PubMed]
36. Alotaibi GF, Bukhari MA. Factors influencing bacterial biofilm formation and development. *Am. J. Biomed. Sci. Res*. 2021 May 21;12(6):617-26. [Google Scholar]
37. Zhao A, Sun J, Liu Y. Understanding bacterial biofilms: From definition to treatment strategies. *Frontiers in cellular and infection microbiology*. 2023 Apr 6;13:1137947. [Google Scholar] [PubMed]
38. Redfern J, Wallace J, van Belkum A, Jaillard M, Whittard E, Ragupathy R, Verran J, Kelly P, Enright MC. Biofilm associated genotypes of multiple antibiotic resistant *Pseudomonas aeruginosa*. *BMC genomics*. 2021 Jul 26;22(1):572. [Google Scholar] [PubMed]
39. Polse RF, Khalid HM, Mero WM. Distribution of *bla* OXA-10, *bla* PER-1, and *bla* SHV genes in ESBL-producing *Pseudomonas aeruginosa* strains isolated from burn patients. *Scientific Reports*. 2023 Oct 26;13(1):18402. [Google Scholar] [PubMed]
40. Abdi FA, Motumma AN, Kalayu AA, Abegaz WE. Prevalence and antimicrobial-resistant patterns of *Pseudomonas aeruginosa* among burn patients attending Yekatit 12 Hospital Medical College in Addis Ababa, Ethiopia. *PloS one*. 2024 Mar 7;19(3):e0289586. [Google Scholar] [PubMed]
41. Dimopoulos G, Akova M, Rello J, Poulakou G. Understanding resistance in *Pseudomonas*. *Intensive care medicine*. 2020 Feb;46(2):350-2. [Google Scholar] [PubMed]
42. Atassi G, Medernach R, Scheetz M, Nozick S, Rhodes NJ, Murphy-Belcaster M, Murphy KR, Alisoltani A, Ozer EA, Hauser AR. Genomics of aminoglycoside resistance in *Pseudomonas aeruginosa* bloodstream infections at a United States Academic Hospital. *Microbiology Spectrum*. 2023 Jun 15;11(3):e05087-22. [Google Scholar] [PubMed]
43. Polse RF, Khalid HM, Mero WM. Molecular Identification and Detection of Virulence Genes among *Pseudomonas aeruginosa* Isolated from Burns Infections. *Journal of Contemporary Medical Sciences*. 2024 Jan 1;10(1). [Google Scholar]
44. Takata I, Yamagishi Y, Mikamo H. Association of the *exoU* genotype with a multidrug non-susceptible phenotype and mRNA expressions of resistance genes in *Pseudomonas aeruginosa*. *Journal of Infection and Chemotherapy*. 2018 Jan 1;24(1):45-52. [Google Scholar] [PubMed]
45. Horna G, Amaro C, Palacios A, Guerra H, Ruiz J. High frequency of the *exoU*+/*exoS*+ genotype associated with multidrug-resistant "high-risk clones" of *Pseudomonas aeruginosa* clinical isolates from Peruvian hospitals. *Scientific Reports*. 2019 Jul 26;9(1):10874. [Google Scholar] [PubMed]
46. Sawa T, Shimizu M, Moriyama K, Wiener-Kronish JP. Association between *Pseudomonas aeruginosa* type III secretion, antibiotic resistance, and clinical outcome: a review. *Critical Care*. 2014 Dec 13;18(6):668. [Google Scholar] [PubMed]
47. Subedi D, Vijay AK, Kohli GS, Rice SA, Willcox M. Association between possession of *ExoU* and antibiotic resistance in *Pseudomonas aeruginosa*. *PloS one*. 2018

- Sep 28;13(9):e0204936. [Google Scholar] [PubMed]
48. Li J, Tang M, Liu Z, Wei Y, Xia F, Xia Y, Hu Y, Wang H, Zou M. Molecular characterization of extensively drug-resistant hypervirulent *Pseudomonas aeruginosa* isolates in China. *Annals of Clinical Microbiology and Antimicrobials*. 2024 Feb 12;23(1):13. [Google Scholar] [PubMed]
 49. Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of *Pseudomonas aeruginosa*. *International journal of antimicrobial agents*. 2005 Apr 1;25(4):290-5. [Google Scholar] [PubMed]
 50. Langendonk RF, Neill DR, Fothergill JL. The building blocks of antimicrobial resistance in *Pseudomonas aeruginosa*: implications for current resistance-breaking therapies. *Frontiers in cellular and infection microbiology*. 2021 Apr 16;11:665759. [Google Scholar] [PubMed]